Clinical Trial Update: RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of RFT5-dgA immunotoxin for relapsed or refractory cutaneous T-cell lymphoma (a form of non-Hodgkin lymphoma) has been terminated with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rft5-Dga

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-12-14